Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoresection versus surgical management for recurrent low-risk non-muscle-invasive bladder cancer
ISRCTN24855462Phase 2Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of mitomycin c in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Complete response to chemoresection at 3 months. Started Jan 2015; status: completed.
02
Drugs
mitomycin c
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ISRCTN24855462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24855462.